Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors

Compounds of the formula: wherein R1 and R2 are each selected from the group consisting of C1-C2 lower alkyl; X is NH or S; and n is a whole number within the range of 1-4 inclusive; and when n=0, X is (CH2)3 and the pharmaceutically acceptable salts thereof have been shown to be effective in treati...

Full description

Saved in:
Bibliographic Details
Main Authors BAUMANN; RUSSELL J, BITONTI; ALAN J
Format Patent
LanguageEnglish
Published 28.10.1997
Edition6
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Compounds of the formula: wherein R1 and R2 are each selected from the group consisting of C1-C2 lower alkyl; X is NH or S; and n is a whole number within the range of 1-4 inclusive; and when n=0, X is (CH2)3 and the pharmaceutically acceptable salts thereof have been shown to be effective in treating tamoxifen resistant tumors. Compounds of the formula: wherein R1 and R2 are each selected from the group consisting of C1-C2 lower alkyl; X is NH or S; and n is a whole number within the range of 1-4 inclusive; and when n=0, X is (CH2)3 and the pharmaceutically acceptable salts thereof have been shown to be effective in treating tamoxifen resistant tumors.
AbstractList Compounds of the formula: wherein R1 and R2 are each selected from the group consisting of C1-C2 lower alkyl; X is NH or S; and n is a whole number within the range of 1-4 inclusive; and when n=0, X is (CH2)3 and the pharmaceutically acceptable salts thereof have been shown to be effective in treating tamoxifen resistant tumors. Compounds of the formula: wherein R1 and R2 are each selected from the group consisting of C1-C2 lower alkyl; X is NH or S; and n is a whole number within the range of 1-4 inclusive; and when n=0, X is (CH2)3 and the pharmaceutically acceptable salts thereof have been shown to be effective in treating tamoxifen resistant tumors.
Author BITONTI; ALAN J
BAUMANN; RUSSELL J
Author_xml – fullname: BAUMANN; RUSSELL J
– fullname: BITONTI; ALAN J
BookMark eNqFjLsKwkAQAK_Qwtc3uD-QQoIhrYhiJYJah03Y04O73eN2BfHrTWFvNTAMM3cTFqaZu5yFq0SGvcTwwT4SDFFSyE9iAmSM8lDwUsAKoSViA_FgmOQdPHFVSIMajtpeSYou3dRjVFr9uHDr4-G2P1WUpSPNOIxj6-7XbdNu2qbe1f-LL1v8OXQ
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
Edition 6
ExternalDocumentID US5681863A
GroupedDBID EVB
ID FETCH-epo_espacenet_US5681863A3
IEDL.DBID EVB
IngestDate Fri Jul 19 14:25:17 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US5681863A3
Notes Application Number: US19940350192
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19971028&DB=EPODOC&CC=US&NR=5681863A
ParticipantIDs epo_espacenet_US5681863A
PublicationCentury 1900
PublicationDate 19971028
PublicationDateYYYYMMDD 1997-10-28
PublicationDate_xml – month: 10
  year: 1997
  text: 19971028
  day: 28
PublicationDecade 1990
PublicationYear 1997
RelatedCompanies MERRELL PHARMACEUTICALS INC
RelatedCompanies_xml – name: MERRELL PHARMACEUTICALS INC
Score 2.4802952
Snippet Compounds of the formula: wherein R1 and R2 are each selected from the group consisting of C1-C2 lower alkyl; X is NH or S; and n is a whole number within the...
SourceID epo
SourceType Open Access Repository
SubjectTerms ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19971028&DB=EPODOC&locale=&CC=US&NR=5681863A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1bS8MwFD7MKeqbTmXe8yB9K8529vJQxLUbQ9gFt8neJLfiYE3G2qE_39OwTV_2FhI4JIFzzXe-ADxQxwtow03tkIW-3eTCs2nDobZwJfco9VxpSFx7fa87ab5Nn6cV-Nr0whie0G9DjogaxVHfC2OvF39FrMRgK_NHNsMp_dIZR4kl1u1ixl9aSStqDwfJILbiOJqMrP57VPJsBZ77ugf7GET7Jfir_dEqe1IW_x1K5wQOhihLFadQkaoGR_Hm37UaHPbWz904XGtefgbDvlZ2hnti2gCx5pLwuc5mJURLEqrKGkxOMAIlW-g40SkpaKZ_ZqlUNqbVZaiI08Uq08v8HO477XHctXFrn9tb-JyMNmdwL6CqtJJ1IC7nTyJMA4djdimYQGsVMiFY2qS-aPjyEuq7pFztXrqGY8PSiibaCW6gWixX8hZ9b8HuzLX9ArSTjbU
link.rule.ids 230,309,783,888,25578,76884
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3dT8IwEL8gGvFNUYOf9MHsbRE3HNvDYmSDoMIgAoY30rVdIGErYSP653trAH3hrbkml2uT--zdrwAP1LBsWjMj3Qmdhl5n3NJpzaA6NwWzKLVMoUBce4HVGdffJ8-TAsy2szAKJ_RbgSOiRjHU90zZ6-VfEctXvZXpYzhHknxpj1xf45txMeUvNb_ptgZ9v-9pnueOh1rw6eY4W7Zlvh7AIQbYdo6y3_pq5jMpy_8OpX0KRwPklWRnUBBJGUre9t-1Mhz3Ns_duNxoXnoOg0AmeowyhVI1Yi0EYQsZz_MWLUFoktdgUoIRKNm1jhMZkYzG8mceiUTHtDoPFZGcrWO5Si-g2m6NvI6Ook13tzAdD7dnMC-hmMhEVICYjD1xJ7INhtklDzlaKyfkPIzqtMFrDXEFlX1crvdvVaHUGfW60-5b8HEDJwqxFc21Yd9CMVutxR364Sy8V1f4C4EckKU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Non-metabolizable+clomiphene+analogs+for+treatment+of+tamoxifen-resistant+tumors&rft.inventor=BAUMANN%3B+RUSSELL+J&rft.inventor=BITONTI%3B+ALAN+J&rft.date=1997-10-28&rft.externalDBID=A&rft.externalDocID=US5681863A